ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA Press release Key Updates September 05, 2017
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong Press release Key Updates August 28, 2017
ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome Press release Key updates May 01, 2017
ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients Press release Key updates April 27, 2017
ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU Press release Key Updates April 03, 2017
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer Press release LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. March 27, 2017
ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update Press release Key updates February 28, 2017
On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day Press release LEIDEN, the Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 27, 2017